» Articles » PMID: 35585481

Lean/normal-weight Metabolic Dysfunction-associated Fatty Liver Disease is a Risk Factor for Reflux Esophagitis

Overview
Journal Hepatol Res
Specialty Gastroenterology
Date 2022 May 18
PMID 35585481
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Reflux esophagitis is associated with metabolic dysfunction. Recently, fatty liver has been redefined as metabolic dysfunction-associated fatty liver disease (MAFLD). We investigated the impact of MAFLD and its subtypes on the incidence of reflux esophagitis.

Methods: This multicenter, observational cohort study enrolled 9100 consecutive health-check examinees who underwent esophagogastroduodenoscopy and ultrasonography. All patients were classified into the MAFLD or non-MAFLD group. Based on the Asian cut-off value for body mass index (BMI), the MAFLD group was further classified into the lean/normal-weight (BMI <23 kg/m ) and overweight/obese (BMI ≥23 kg/m ) subgroups. The impact of MAFLD and its subtypes on the cumulative incidence of reflux esophagitis was evaluated using multivariable Cox proportional hazards regression analysis.

Results: MAFLD was diagnosed in 26.5% (2416/9100) of patients. Multivariable Cox proportional hazards regression analysis indicated that MAFLD (hazard ratio [HR] 1.2183; 95% confidence interval [CI] 1.0954-1.3550; p = 0.0003), hiatal hernia, and aging were independent risk factors for reflux esophagitis. Stratification analysis indicated that cumulative incidence of reflux esophagitis among patients with MAFLD was significantly higher in the lean/normal-weight than in the overweight/obese group (HR 1.3274; 95% CI 1.0043-1.7547; p = 0.0466). Among various metabolic factors, visceral adiposity was the only independent metabolic risk factor for reflux esophagitis (HR 2.8331; 95% CI 1.0201-7.8691; p = 0.0457) in the lean/normal-weight MAFLD group.

Conclusions: MAFLD, in particular lean/normal-weight MAFLD, is independent risk factor for reflux esophagitis. Furthermore, visceral adiposity was identified as the most strong metabolic risk factor for reflux esophagitis in lean/normal-weight patients with MAFLD.

Citing Articles

Relationship of different metabolic obesity phenotypes with reflux esophagitis: a propensity score matching analysis.

He T, Wang P, Wang L, Tong M, Duan Z BMC Endocr Disord. 2024; 24(1):239.

PMID: 39506726 PMC: 11542364. DOI: 10.1186/s12902-024-01771-6.


Nomogram for predicting reflux esophagitis with routine metabolic parameters: a retrospective study.

He T, Sun X, Duan Z Arch Med Sci. 2024; 20(4):1089-1100.

PMID: 39439693 PMC: 11493045. DOI: 10.5114/aoms/175536.


Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.

Suoh M, Esmaili S, Eslam M, George J Hepatol Int. 2024; 18(6):1740-1755.

PMID: 39412611 PMC: 11632019. DOI: 10.1007/s12072-024-10731-0.


Association Between Different Metabolic Obesity Phenotypes and Erosive Esophagitis: A Retrospective Study.

He T, Sun X, Tong M, Zhang M, Duan Z Diabetes Metab Syndr Obes. 2024; 17:3029-3041.

PMID: 39166154 PMC: 11334917. DOI: 10.2147/DMSO.S471499.


Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A....

Kim G, Jeong S, Jang H, Lee D, Joo S, Kim W Liver Cancer. 2024; 13(4):426-437.

PMID: 39114758 PMC: 11305668. DOI: 10.1159/000535943.